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Abstract
Purpose—The cytochrome P450 2C9 enzyme (CYP2C9) is involved in metabolism of
endogenous compounds, drugs and procarcinogens. Two common nonsynonymous
polymorphisms in CYP2C9 are associated with reduced enzyme activity: CYP2C9*2 (rs1799853,
R144C) and CYP2C9*3 (rs1057910, I359L).
Methods—We investigated whether CYP2C9 genotype was associated with risk of colorectal
adenoma and/or modified associations with aspirin treatment or cigarette smoking in a cohort of
928 participants in a randomized trial of aspirin chemoprevention. Generalized linear regression
was used to compute relative risks (RRs) and 95% confidence intervals (95% CIs). Multiplicative
interactions terms were used to assess effect modification.
Results—CYP2C9 genotype was associated with increased risks for adenoma recurrence of 29%
(RR=1.29, 95% CI =1.09–1.51) for ≥1 variant allele (CYP2C9*2 or *3) and 47% (RR=1.47, 95%
CI=1.19–1.83) for ≥1 CYP2C9*3 allele. The risk for advanced lesions or multiple (≥3) adenomas
was increased by 64% (RR=1.64, 95% CI=1.18–2.28) for ≥1 variant allele (CYP2C9*2 or *3) and
79% (RR=1.79, 95% CI=1.16–2.75) for ≥1 CYP2C9*3 allele. Genotype modified associations
with smoking, but not aspirin treatment. The adenoma risk was increased by 26% (RR=1.26, 95%
CI=0.99–1.58) for former smokers and 60% (RR=1.60, 95% CI=1.19–2.15) for current smokers
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among wild-type individuals, but there was no increased risk among individuals with ≥1 variant
allele (CYP2C9*2 or *3) (Pinteraction=0.04).
Conclusions—Carriers of CYP2C9 variants with lower enzyme activity have increased overall
risk of colorectal adenoma but reduced adenoma risk associated with cigarette smoking. These
results may be due to effects on the synthesis of endogenous eicosanoids and/or reduced activation
of procarcinogens in smoke by CYP2C9 variants.
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Introduction
As the second leading cause of cancer deaths in the United States, colorectal cancer is a
major public health problem (1). Thus, it is important to investigate how genetic and
environmental factors, and their interactions, contribute to colorectal neoplasia. The human
cytochrome P450 (CYP) superfamily includes 57 genes encoding enzymes involved in the
metabolism of xenobiotics, including drugs and environmental toxins, as well as numerous
endogenous compounds (2). CYP2C9 is thought to be involved in the inactivation of 10–
30% of clinically useful drugs, the synthesis of important endogenous signaling molecules
(i.e., arachidonic acid epoxides), as well as the activation of pro-carcinogenic compounds in
tobacco smoke to carcinogenic metabolites (2–7). Notably, common polymorphisms in the
CYP2C9 gene modify its enzymatic activity (8–11) and thereby influence response to drugs,
such as warfarin (12), and may also modify the effects of endogenous compounds and toxins
from cigarette smoke. Previous research suggests that CYP2C9 polymorphisms may be
associated with risk of colorectal adenomas or cancer and/or modify the protective effect of
aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) (13–19). In the present
study, we investigated associations of two common CYP2C9 polymorphisms with risk of
adenoma recurrence and interactions with aspirin treatment and smoking status among
participants in a randomized clinical trial of aspirin and folate for the prevention of adenoma
recurrence.
Materials and Methods
Study Design and Population
We performed an observational (prospective cohort) analysis of the association between
CYP2C9 genotypes and risk of colorectal neoplasia among participants in the Aspirin/Folate
Polyp Prevention Study, a placebo-controlled, randomized clinical trial of aspirin and/or
folic acid for the prevention of colorectal adenoma recurrence. The parent study design and
main findings have been described in detail previously (20, 21). In brief, 1121 participants,
who were recruited from 9 clinical centers between 1994 and 1998, had a recent history of
one or more histologically confirmed colorectal adenoma and a complete colonoscopy
within 3 months prior to enrollment with all known polyps removed from the bowel.
Participants agreed to avoid NSAID use during their participation in the study and were
randomized to aspirin treatment (placebo, 81 or 325 mg daily) and, independently, to folic
acid treatment (placebo or 1 mg daily) in a 3 × 2 factorial design. Per protocol, aspirin
treatment was to be continued until a follow-up colonoscopy was performed three years after
the baseline colonoscopy. Compliance was excellent. Endpoint data included an assessment
of size, number, histology and location of all colorectal lesions detected during randomized
aspirin treatment. A single, blinded, study pathologist provided uniform review of all
clinical samples removed from the large bowel.
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Of the 1048 randomized subjects with adenoma outcome data, 928 were genotyped (88.5%);
120 subjects could not be genotyped due to lack of subject consent or local IRB approval.
TaqMan-based assays were performed on two common non-synonymous polymorphisms,
CYP2C9*2 (R144C, rs1799853) and CYP2C9*3 (I359L, rs1057910), at the Fred
Hutchinson Cancer Research Center using the Applied Biosystems 7900HT Sequence
Detection System (Applied Biosystems, Foster City, CA). Genotypes were assigned using
the Allelic Discrimination Software (Applied Biosystems SDS Software, version 2.3).
Primers and cycling conditions are available upon request. For quality control, 7% of the
total number of samples were re-genotyped to validate genotype identification protocols.
Call rates for all four genotypes exceeded 99% and all were in Hardy-Weinberg equilibrium
(p>0.05). Concordance for blinded duplicates was 100%. Laboratory staff were blinded to
case-control status for all assays.
Statistical Analysis
The principal outcome was a finding of at least one traditional adenoma at a follow-up
colonoscopy after at least one year of randomized treatment and up until the end of
randomized aspirin treatment. A secondary “high-risk” outcome was defined as a finding of
at least one advanced lesion (a traditional adenoma ≥ 1cm in size, or with villous histology
or high grade dysplasia, or cancinoma) and/or multiple adenomas (≥ 3 traditional
adenomas). Notably, lesions in the serrated pathway are not included in these outcomes (i.e.
serrated or sessile serrated adenomas with or without dysplasia). Risk ratios and 95%
confidence intervals used to estimate the association between genotype and outcome were
calculated with generalized linear regression models using the Poisson distribution as an
approximation to the binomial family and corrected for over or under dispersion. Models
were adjusted for age and sex. Genotypes were analyzed using a dominant genetic model
due to the limited number of variant homozygotes. For the combined genotype analyses, the
variant genotype was defined as having ≥ 1 variant allele of either type (CYP2C9*2 or *3)
to maximize power. We also evaluated whether aspirin treatment or smoking status
interacted with genotype to modify associations with risk of colorectal neoplasia using
multiplicative interaction terms in the regression models and Wald tests. Smoking was
defined by self-report as “one cigarette or more each day for a year or more”. Analyses that
included aspirin treatment were conducted according to the intention-to-treat principle.
Comparisons of selected subject or study characteristics between the groups with and
without adenoma recurrence or between groups with wildtype vs. variant genotypes used
Pearson χ2 tests for categorical variables or two sample t tests for continuous variables.
Race/ethnicity was collected by self-report; analyses were performed on all races and on
non-Hispanic whites only. All statistical tests were two-sided and considered significant at a
value of P<0.05. Stata (version 10) was used for all analyses.
Results
Demographic and other selected characteristics of genotyped participants at enrollment in
the Aspirin/Folate Polyp Prevention Study are presented in Table 1 overall (total) and by the
primary outcome (adenoma recurrence). Among the 925 genotyped participants, 377
(40.8%) had a recurrence of one or more colorectal adenomas during an average follow-up
period of 32.8 months. A higher proportion of participants with adenoma recurrence were
current or former smokers (17.1 and 44.5%, respectively) compared to those without
adenoma recurrence (12.1 and 41.9%, respectively)(P=0.03). As previously reported for the
entire study population (20), individuals in this genotyped subset randomized to treatment
with 81 mg/day of aspirin appeared less likely to have adenoma recurrence (30%) compared
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with those randomized to the placebo arm (35.8%) or to treatment with 325 mg/day aspirin
(34.2%)(P=0.09).
Overall, among all genotyped participants, 213 (23%) had one or more CYP2C9*2 variant
alleles (minor allele frequency (MAF)=12.2%), 101 (10.9%) had one or more CYP2C9*3
variant alleles (MAF=5.5%) and 298 participants (32.3%) had one or more variant allele of
either type (combined genotype) (Table 1). Notably, a higher proportion of individuals with
adenoma recurrence had a CYP2C9*3 variant genotype (15.1%) compared to those without
adenoma recurrence (8%) (P=0.002), whereas the proportion of CYP2C9*2 variant
genotype was similar between the two groups (P=0.30). When the CYP2C9 combined
genotype was examined, a higher proportion of individuals with adenoma recurrence had
one or more variant alleles (38.3%) compared to those without adenoma recurrence (28.1%)
(P=0.001).
As shown in Table 2, most subject and study characteristics did not differ by CYP2C9
genotype, including age, sex, aspirin or folate treatment groups and mean follow-up time.
However, the CYP2C9*2 genotype was associated with race/ethnicity: a higher proportion
of individuals with one or more variant alleles were non-Hispanic white (94.4%) compared
to the proportion of wild type individuals that were non-Hispanic white (84%) (P=0.001). In
addition, the CYP2C9*3 genotype appeared to be associated with smoking status, such that
a higher proportion of individuals with one or more variant alleles were former (45.5%) or
current smokers (20.8%) compared to the proportion of wild type individuals that were
former (42.6%) or current smokers (13.3%)(P=0.05).
We examined the association of CYP2C9 genotypes with risk of colorectal neoplasia during
the period of randomized aspirin treatment by assessing the occurrence of any adenoma or
of advanced lesions/multiple adenomas (Table 3). The combined variant genotype (one or
more variant allele of either type) was associated with statistically significant increased risks
of 29% for any adenoma (RR=1.29, 95% CI=1.09–1.51, P=0.002) and 64% for advanced
lesions or multiple adenomas (RR=1.64; 95% CI=1.18–2.28, P=0.003). The increase in risk
was mostly due to the CYP2C9*3 genotype: having one or more variant allele was
associated with increased risks of 47% (RR=1.47, 95% CI=1.19–1.83, P<0.001) for any
adenoma and 79% (RR=1.79, 95% CI=1.16–2.75, P=0.008) for advanced lesions or multiple
adenomas. However, the CYP2C9*2 variant was also associated with non-statistically
significant increased risks, especially for the “high-risk” findings (advanced lesions or
multiple adenomas). As shown in Table 3, very similar results were observed when the
analyses were restricted to non-Hispanic whites (86.2% of the study population).
We also investigated whether CYP2C9 genotype modified the effect of aspirin treatment or
the association of smoking status with risk of any adenoma (Table 4). Among all genotyped
participants, the lower dose of aspirin treatment (81 mg) reduced risk by 19% (RR=0.81,
95% CI=0.67–0.98, P=0.03) whereas the higher dose (325 mg) appeared ineffective
(RR=0.94 RR, 95% CI=0.78–1.13, P=0.48) (not shown). When aspirin treatment was
stratified by CYP2C9 genotype (Table 4), similar results were obtained regardless of
genotype and there was no evidence for an interaction of genotype and aspirin treatment.
Notably, the results were similar when this analysis was restricted to non-Hispanic whites
(Table 4) or to the CYP2C9*3 genotype (not shown). In addition, CYP2C9 genotype also
did not modify the effect of folate treatment (not shown).
On the other hand, there was evidence for an interaction between smoking status and
CYP2C9 genotype (Table 4). Among participants with the wild-type CYP2C9 genotype,
smoking was associated with increased adenoma risks of 26% (RR=1.26, 95% CI=0.99–
1.58) for former smokers and 60% (RR=1.60, 95% CI=1.19–2.15) for current smokers.
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However, in participants with one or more variant alleles of either type, smoking status was
not associated with increased risks: RR=0.80 (95% CI=0.62–1.03) in former smokers and
RR=1.03 (95% CI=0.72–1.50) in current smokers. In this stratified analysis, the combined
CYP2C9 variant genotype (one or more variant allele of either type) was associated with a
67% increased risk of adenoma among non-smokers (RR=1.67, 95% CI= 1.30–2.16, Table 4
footnote) compared to the 29% increased risk seen in all subjects (Table 3). Similar results
were seen when the analyses were restricted to non-Hispanic whites. The interaction
between smoking status and CYP2C9 genotype was statistically significant for all
participants (P=0.04) as well as for non-Hispanic whites (P=0.04). When this analysis was
restricted to the CYP2C9*3 genotype, similar results were seen, although the interaction was
not statistically significant (not shown).
Discussion
In this prospective analysis of participants from a randomized clinical trial of aspirin for
colorectal adenoma chemoprevention, CYP2C9 genotype was associated with increased
risks of any adenoma of 29% for ≥1 variant of either type (CYP2C9*2 or *3) and 47% for
≥1 CYP2C9*3 variant. Moreover, the associations with “high-risk” findings (multiple
adenomas (≥3) and/or advanced lesions), appeared larger: risks increased by 64% for ≥1
variant of either type (CYP2C9*2 or *3) and 79% ≥1 CYP2C9*3 variant. In addition,
although CYP2C9 genotype didn’t modify the protective effect of aspirin on adenoma risk,
it substantially modified the association with smoking such that former or current smoking
was only associated with increased risk of adenoma among participants with the wild-type
CYP2C9 genotype.
There is evidence from recent tissue microarray experiments that the CYP2C9 enzyme is
broadly expressed in human tissues, including moderate expression in the colon (22), and is
the most abundantly expressed epoxygenase in several human malignant neoplasms (23).
The stronger association of CYP2C9 genotype with “high-risk” findings (advanced and
multiple adenomas) in the current study is noteworthy because of the potential clinical
importance of these lesions, given their association with greater risk for future advanced
neoplasia and cancer (24). Importantly, we observed similar results when our analyses were
restricted to non-Hispanic whites, mitigating concerns about potential effects of population
stratification. In addition, the reduction in enzyme activity for the CYP2C9*3 variant is
more substantial than for the CYP2C9*2 variant (8–10), so the stronger associations
observed with the CYP2C9*3 variant genotype in the current work is consistent with a role
for this enzyme in modulating adenoma risk. However, others have suggested that
associations with the CYP2C9*2 genotype may actually be due to linkage disequilibrium
with the CYP2C8*3 variant rather than a true effect of the CYP2C9 polymorphism (see (11,
17, 25, 26)).
A number of previous studies have investigated associations of these CYP2C9
polymorphisms with colorectal adenomas and cancer. Among previous studies of CYP2C9
genotype and adenoma risk, Chan et al. also reported a statistically significant increase in
risk of distal adenoma associated with combined (CYP2C9*2 or *3) variant genotype in the
Nurses Health Study (14). However, there were only modest, non-statistically significant
increased risks in several other studies (13, 15, 17) and one report of decreased risk in a
small Scottish case-control study (19).
Among these prior studies, one reported that CYP2C9 genotype modified the protective
association with aspirin, although it was not clear if this interaction was statistically
significant (13), whereas two others noted no interaction (14, 15). Our trial, with its larger
size and randomized aspirin intervention, was well suited to address this issue, which was a
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major impetus for the current work (27, 28). However, since the CYP2C9 enzyme is thought
to have a relatively minor role in metabolizing aspirin (10), it is perhaps not surprising that
we did not find an interaction. Only one of the previously mentioned studies investigated the
interaction between genotype and smoking on adenoma prevalence, and no association was
found (14). Of studies investigating associations with colorectal cancer risk, the two largest
reported either no association (16) or a decreased risk associated with the CYP2C9*2
genotype (18), and no interaction with aspirin (16) or smoking (18).
The apparent association of CYP2C9*3 genotype with smoking status in our study
population may be a chance finding or may reflect a previously unrecognized role for this
enzyme in metabolizing nicotine. Although a large genome wide association study meta-
analysis did not identify genetic variation in the vicinity of this gene to be associated with
smoking behaviors (29), it is possible that there were effects that were not detected at a
genome wide significance level. Interestingly, the CYP2C9 gene is located on chromosome
10q24 and a marker in the adjacent 10q25 region was associated with smoking behavior in a
study of twins from Finland (30). In addition, another member of the CYP2 gene family,
CYP2A6, has been associated with smoking behaviors and lung cancer risk (31).
The mechanism by which CYP2C9 genotype may increase adenoma risk is not known.
However, the CYP2C9 enzyme may play a role in the metabolism of arachidonic acid to
eicosanoids, specifically to epoxyeicosatrienoic acid, and may ultimately influence
carcinogenesis through effects on cellular proliferation and inflammation (2, 3, 8). In
addition to effects on endogenous modulators, CYP2C9 may be involved in the metabolism
of environmental carcinogens impacting colorectal carcinogenesis. The attenuated risk
associated with cigarette smoking among participants with the variant genotype in the
current study could be explained by a role for CYP2C9 in activation of procarcinogenic
chemicals such as polycyclic aromatic hydrocarbons found in tobacco smoke (4–7, 32) (33).
The increased adenoma risk associated with smoking observed in our population is
consistent with the results of published meta-analyses for colorectal adenoma (34) and
cancer (35, 36). Since smoking appears to increase risk of certain histologically and
molecularly defined subsets of colorectal cancer (37, 38)), which can also result in
differential interactions (see(39)), it will be important to explore associations with CYP2C9
genotype among these subsets in future studies. Likewise, it seems possible that differences
in the types of pre-cancerous lesions examined and/or smoking status among different study
populations may explain some of the heterogeneity observed in published studies of
associations between CYP2C9 genotype and adenoma risk and this will be an important
avenue for future exploration.
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